CLINICAL & PIPELINE·Drug Approval
Cipla Secures FDA Approval for Generic Dihydroergotamine Mesylate Nasal Spray (ANDA212907)
Cipla USA Inc. received FDA approval for its generic DIHYDROERGOTAMINE MESYLATE NASAL spray (ANDA212907) on May 20, 2020, with a labeling update on September 12, 2023. This "AB" rated therapeutic equivalent product offers procurement directors a cost-effective alternative, intensifying competition in the nasal spray market. Supply chain VPs should anticipate pricing pressure, while business development executives can leverage increased market access for this critical medication.
90-Day Activity